TY - JOUR
T1 - Is there a preferred combination chemotherapy regimen for metastastic non-small cell lung cancer?
AU - Ettinger, David S.
PY - 2002
Y1 - 2002
N2 - Since over 70% of patients with non-small cell lung cancer (NSCLC) have advanced (locally advanced or metastatic) disease, the majority of NSCLC patients might benefit from chemotherapy. During the past decade, a number of new agents (paclitaxel, docetaxel, gemcitabine, vinorelbine, irinotecan, and topotecan) have been found to be effective against lung cancer. These agents have been combined with cisplatin, carboplatin, and nonplatinum drugs to treat NSCLC. They, in general, produce median survival times of 8-10 months and 1- and 2-year survival rates of 35%-40% and 10%-15%, respectively. Based on this review, there is not a preferred combination chemotherapy regimen to treat advanced NSCLC patients. However, there are a number of different regimens from which to choose.
AB - Since over 70% of patients with non-small cell lung cancer (NSCLC) have advanced (locally advanced or metastatic) disease, the majority of NSCLC patients might benefit from chemotherapy. During the past decade, a number of new agents (paclitaxel, docetaxel, gemcitabine, vinorelbine, irinotecan, and topotecan) have been found to be effective against lung cancer. These agents have been combined with cisplatin, carboplatin, and nonplatinum drugs to treat NSCLC. They, in general, produce median survival times of 8-10 months and 1- and 2-year survival rates of 35%-40% and 10%-15%, respectively. Based on this review, there is not a preferred combination chemotherapy regimen to treat advanced NSCLC patients. However, there are a number of different regimens from which to choose.
KW - Combination chemotherapy
KW - Metastatic non-small cell lung cancer
KW - Phase III studies
UR - http://www.scopus.com/inward/record.url?scp=0036076240&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036076240&partnerID=8YFLogxK
U2 - 10.1634/theoncologist.7-3-226
DO - 10.1634/theoncologist.7-3-226
M3 - Review article
C2 - 12065795
AN - SCOPUS:0036076240
SN - 1083-7159
VL - 7
SP - 226
EP - 233
JO - Oncologist
JF - Oncologist
IS - 3
ER -